Supplementary Figure S14 from Autocrine 17-β-Estradiol/Estrogen Receptor-α Loop Determines the Response to Immune Checkpoint Inhibitors in Non–Small Cell Lung Cancer

<p>Effects of letrozole on the efficacy of chemo-immuno-therapy in non-small cell lung cancer xenografts. 1×106 female-derived ERα lowNCI-H1385 cells and ERα highNCI-H1975 cells, male-derived ERα lowA549 cells and ERα highNCI-H1650 cells were implanted subcutaneously (s.c.) in Hu-CD34+NSG mice. When tumors reached the volume of 100 mm3, mice (n= 5/group) were randomized in the following groups: 1) Vehicle group, treated intraperitoneally (i.p.) with 100 µl saline solution (days 1, 7, 14, 21, 28, 35 after randomization); 2) cisplatin (PT) group, treated with 2 mg/kg intravenously (i.v.) (days 7, 14, 21, 28, 35); 3) cisplatin + pembrolizumab (PT+Pemb) group, treated with 2 mg/kg cisplatin i.v. (days 7, 14, 21, 28, 35) and 10 mg/kg i.p. of 100 µl saline solution of pembrolizumab (day 1) followed by 5 mg/kg i.p. (days 7, 14, 21, 28, 35); 4) cisplatin + pembrolizumab + letrozole (PT+Pemb+Letr) group, treated with 2 mg/kg cisplatin i.v. (days 7, 14, 21, 28, 35), 10 mg/kg i.p. of 100 µl saline solution of pembrolizumab (day 1) followed by 5 mg/kg i.p. (days 7, 14, 21, 28, 35) and 1 mg/kg per os of 100 µl saline solution of letrozole daily (days 1-35). Tumor growth was monitored daily with a caliper. Mice were euthanized on day 40. Data are mean volumes+SD. **p<0.01, ***p<0.001: treatments group versus Vehicle group (day 40); °°°p<0.001: PT+Pemb+Letr group versus Pemb+Letr group (day 40; ANOVA).</p>